Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Freeline Therapeutics (FRLN)

Freeline Therapeutics Holdings PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FRLN
DateTimeSourceHeadlineSymbolCompany
24/04/202421:00GlobeNewswire Inc.Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:FRLNFreeline Therapeutics Holdings PLC
26/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202421:38Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202421:36Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202421:33Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202421:32Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202421:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202420:22Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202412:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202412:00GlobeNewswire Inc.Acquisition of Freeline by Syncona Becomes EffectiveNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/02/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/02/202417:00GlobeNewswire Inc.Freeline Shareholders Approve Acquisition by SynconaNASDAQ:FRLNFreeline Therapeutics Holdings PLC
18/01/202421:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
17/01/202421:17Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/12/202322:21Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:FRLNFreeline Therapeutics Holdings PLC
01/12/202313:56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/11/202314:20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/11/202312:30GlobeNewswire Inc.Syncona to Acquire Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/10/202311:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/10/202307:01GlobeNewswire Inc.Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
18/10/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
16/10/202312:00GlobeNewswire Inc.Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
06/10/202321:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/10/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/10/202312:00GlobeNewswire Inc.Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
15/08/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
15/08/202312:00GlobeNewswire Inc.Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/08/202312:30GlobeNewswire Inc.Freeline Therapeutics to Host Second Quarter 2023 Financial Results CallNASDAQ:FRLNFreeline Therapeutics Holdings PLC
31/07/202312:30GlobeNewswire Inc.Freeline to Participate in Upcoming Investor ConferencesNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/07/202312:30GlobeNewswire Inc.Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:FRLN